KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBT Margin: 2010-2025

Historic EBT Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -297.04%.

  • Nektar Therapeutics' EBT Margin fell 14347.00% to -297.04% in Q3 2025 from the same period last year, while for Sep 2025 it was -181.81%, marking a year-over-year decrease of 109.00%. This contributed to the annual value of -121.13% for FY2024, which is 18540.00% up from last year.
  • Nektar Therapeutics' EBT Margin amounted to -297.04% in Q3 2025, which was up 15.74% from -352.53% recorded in Q2 2025.
  • Nektar Therapeutics' EBT Margin's 5-year high stood at 23.91% during Q4 2024, with a 5-year trough of -736.47% in Q2 2022.
  • Its 3-year average for EBT Margin is -260.57%, with a median of -222.73% in 2024.
  • As far as peak fluctuations go, Nektar Therapeutics' EBT Margin slumped by 29,467bps in 2022, and later soared by 48,686bps in 2023.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' EBT Margin stood at -587.02% in 2021, then skyrocketed by 29,887bps to -288.16% in 2022, then spiked by 11,186bps to -176.29% in 2023, then spiked by 20,020bps to 23.91% in 2024, then tumbled by 14,347bps to -297.04% in 2025.
  • Its last three reported values are -297.04% in Q3 2025, -352.53% for Q2 2025, and -443.30% during Q1 2025.